One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults

被引:44
作者
Boguszewski, CL [1 ]
Meister, MHF [1 ]
Zaninelli, DCT [1 ]
Radominski, RB [1 ]
机构
[1] Univ Fed Parana, Hosp Clin, Serv Endocrinol & Metab, BR-80060000 Curitiba, Parana, Brazil
关键词
D O I
10.1530/eje.1.01817
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We have studied the effects on body composition and metabolism of a fixed low dose of growth hormone (GH), 0.6 IU (0.2 mg)/day, administered for 12 months to GH-deficient (GHD) adults. Design and methods: Prospective open-label study, using 1.8 GHD patients (11 women, 7 men; aged 21-58 years). All investigations were performed at baseline and after 12 months. Body composition was determined by dual energy X-ray absorptiometry. Results: Total body rat decreased (- 1.74 +/- 2.87%) and tean body mass (LBM) increased (1.27 +/- 2.08 kg) after therapy (P < 0.05). Changes in truncal fat did not reach statistical significance, but a decrease varying from 0.72 to 2.78 kg (1 to 8.7%) was observed in 13 (72%) patients, Bone mineral density (BMD) increased at lumbar spine. total femur and femoral neck (P < 0.05). Levels of total and low-density lipoprotein (LDL)-cholesterol were lower after therapy (P < 0.05), and their changes were directly associated with values at baseline. lnsulin levels increased kind the insulin resistance index worsened at 12 months (P < 0.05). Median IGF-I S.D. score was - 4.30 (range, - 11.03 to - 0.11) at baseline and - 1.73 (range, - 9.80 to 2.26) at 12 months. Normal age-adjusted IGF-I levels were obtained with therapy in 5 of 11 patients who had low IGF-I levels at baseline. Changes in IGF-I levels were not correlated with any biological end point, except changes in LBM (r = 0.53, P = 0.02). Side effects were mild and disappeared spontaneously. Conclusions: One-year of a fixed low-dose GH regimen in GHD adults resulted in a significant reduction in body fat, total cholesterol and LDL-cholesterol, and a significant increase in LBM and BMD at lumbar spine and femur, regardless of normalization of IGF-I levels. This regimen led to an elevation of insulin levels and a worsening of the insulin resistance index.
引用
收藏
页码:67 / 75
页数:9
相关论文
共 35 条
[1]   Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies [J].
Abrahamsen, B ;
Hangaard, J ;
Horn, HC ;
Hansen, TB ;
Gregersen, G ;
Hansen-Nord, M ;
Vahl, N ;
Junker, P ;
Andersen, M ;
Hagen, C .
CLINICAL ENDOCRINOLOGY, 2002, 57 (02) :273-281
[2]  
Abrams P, 2004, GROWTH HORMONE DEFIC, P127
[3]   Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects [J].
Amato, G ;
Izzo, G ;
LaMontagna, G ;
Bellastella, A .
CLINICAL ENDOCRINOLOGY, 1996, 45 (01) :27-32
[4]  
Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379
[5]   Treatment of growth hormone deficiency in adults [J].
Bengtsson, BÅ ;
Johannsson, G ;
Shalet, SM ;
Simpson, H ;
Sonken, PH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (03) :933-937
[6]   TREATMENT OF ADULTS WITH GROWTH-HORMONE (GH) DEFICIENCY WITH RECOMBINANT HUMAN GH [J].
BENGTSSON, BA ;
EDEN, S ;
LONN, L ;
KVIST, H ;
STOKLAND, A ;
LINDSTEDT, G ;
BOSAEUS, I ;
TOLLI, J ;
SJOSTROM, L ;
ISAKSSON, OGP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 76 (02) :309-317
[7]   THE EFFECT OF GROWTH-HORMONE ADMINISTRATION IN GROWTH-HORMONE DEFICIENT ADULTS ON BONE, PROTEIN, CARBOHYDRATE AND LIPID HOMEOSTASIS, AS WELL AS ON BODY-COMPOSITION [J].
BINNERTS, A ;
SWART, GR ;
WILSON, JHP ;
HOOGERBRUGGE, N ;
POLS, HAP ;
BIRKENHAGER, JC ;
LAMBERTS, SWJ .
CLINICAL ENDOCRINOLOGY, 1992, 37 (01) :79-87
[8]   The effect of growth hormone (GH) on histomorphometric indices of bone structure and bone turnover in GH-deficient men [J].
Bravenboer, N ;
Holzmann, P ;
DeBoer, H ;
Roos, JC ;
VanderVeen, EA ;
Lips, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (06) :1818-1822
[9]   Guidelines for optimizing growth hormone replacement therapy in adults [J].
de Boer, H ;
van der Veen, E .
HORMONE RESEARCH, 1997, 48 :21-30
[10]   Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults [J].
Drake, WM ;
Coyte, D ;
Camacho-Hübner, C ;
Jivanji, NM ;
Kaltsas, G ;
Wood, DF ;
Trainer, PJ ;
Grossman, AB ;
Besser, GM ;
Monson, JP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (11) :3913-3919